A panel of independent experts to the C.D.C. says it needs more time to assess data and risks during the Johnson & Johnson vaccine pause.
An advisory committee for the Centers for Disease Control and Prevention met on Wednesday to discuss the decision made on Tuesday to pause use of the Johnson & Johnson Covid-19 vaccine because of its possible link to extremely rare blood clots. After a robust afternoon discussion, the panel decided they needed more time to assess…